Cell surface CD28 levels define four CD4+ T cell subsets : abnormal expression in rheumatoid arthritis

Copyright 2001 Academic Press.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 99(2001), 2 vom: 15. Mai, Seite 253-65
1. Verfasser: Salazar-Fontana, L I (VerfasserIn)
Weitere Verfasser: Sanz, E, Mérida, I, Zea, A, Sanchez-Atrio, A, Villa, L, Martínez-A, C, de la Hera, A, Alvarez-Mon, M
Format: Aufsatz
Sprache:English
Veröffentlicht: 2001
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't CD28 Antigens DNA Primers Interleukin-2 RNA, Messenger Receptors, Interleukin-2 Leukocyte Common Antigens EC 3.1.3.48
LEADER 01000naa a22002652 4500
001 NLM112268528
003 DE-627
005 20231222161404.0
007 tu
008 231222s2001 xx ||||| 00| ||eng c
028 5 2 |a pubmed24n0375.xml 
035 |a (DE-627)NLM112268528 
035 |a (NLM)11318597 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Salazar-Fontana, L I  |e verfasserin  |4 aut 
245 1 0 |a Cell surface CD28 levels define four CD4+ T cell subsets  |b abnormal expression in rheumatoid arthritis 
264 1 |c 2001 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 31.05.2001 
500 |a Date Revised 16.11.2017 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Copyright 2001 Academic Press. 
520 |a CD28 is a costimulatory receptor expressed in most CD4(+) T cells. Despite the long-standing evidence for up- and downregulation of surface CD28 expression in vitro, and the key regulatory role assigned to the upregulation of CD28 counterreceptor [the CD152 (CTLA-4) molecule], in vivo CD28 induction has attracted little attention. We studied CD28 and CD152 expression and function in 33 rheumatoid arthritis (RA) patients, 20 clinically active and 13 inactive, and in 24 healthy donors. Four subsets of CD28(-), CD28(low), CD28(int), and CD28(high) peripheral blood human CD4(+) T cells were defined using three-color flow cytometry. The three CD28(+) subsets displayed a one-, two-, or threefold quantitative difference in their relative number of CD28 antibody binding sites, respectively (P < 0.01). RA patients, whether active or inactive, showed a distinct phenotype when compared to healthy donors: (i) the percentage of CD4(+)CD28(high) cells was increased twofold and the CD4(+)CD28(low) subset was reduced twofold (P < 0.01) and (ii) the CD4(+)CD28(high) cells from RA patients showed an in vivo activated phenotype, CD45RO(+)CD5(high)IL-2Ralpha(+) (P < 0.01). Active RA patients were different from inactive patients. They showed a twofold increase in mean CD28 expression (P < 0.05), whereas each of the CD28(+) subsets in the inactive RA patients showed reduced expression when compared to healthy donors. Notably, both active and inactive RA patients showed abnormal CD28 upregulation when T cells were activated in vitro with CD3 antibodies, but only inactive RA patients showed a hypoproliferative response to TCR/CD3 triggering when compared to healthy donors (P < 0.01). This defective proliferation was normalized by concurrent crosslinking with CD28 antibody. No differences were noted in the expression of CD152 or CD80, a CD28 and CD152 shared ligand. The disregulated in vivo expression of CD28 was related to the RA patients' disease activity and suggests that modulation of CD28 surface levels may be an additional mechanism to finely tune the delicate responsiveness/tolerance balance 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a CD28 Antigens  |2 NLM 
650 7 |a DNA Primers  |2 NLM 
650 7 |a Interleukin-2  |2 NLM 
650 7 |a RNA, Messenger  |2 NLM 
650 7 |a Receptors, Interleukin-2  |2 NLM 
650 7 |a Leukocyte Common Antigens  |2 NLM 
650 7 |a EC 3.1.3.48  |2 NLM 
700 1 |a Sanz, E  |e verfasserin  |4 aut 
700 1 |a Mérida, I  |e verfasserin  |4 aut 
700 1 |a Zea, A  |e verfasserin  |4 aut 
700 1 |a Sanchez-Atrio, A  |e verfasserin  |4 aut 
700 1 |a Villa, L  |e verfasserin  |4 aut 
700 1 |a Martínez-A, C  |e verfasserin  |4 aut 
700 1 |a de la Hera, A  |e verfasserin  |4 aut 
700 1 |a Alvarez-Mon, M  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 99(2001), 2 vom: 15. Mai, Seite 253-65  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:99  |g year:2001  |g number:2  |g day:15  |g month:05  |g pages:253-65 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 99  |j 2001  |e 2  |b 15  |c 05  |h 253-65